3 Evaluation of HO-1 involvement in melanoma resistance to BRAF inhibitor vemurafenib
Sign Up to like & getrecommendations! Published in 2018 at "Postgraduate Medical Journal"
DOI: 10.1136/postgradmedj-2018-fpm.14
Abstract: Introduction The point mutation of the BRAF gene (BRAFV600E) is present in more than 50% of melanoma. This mutation determinate the continuous activation of MAPK pathway, which favours cell survival and proliferation. Vemurafenib/PLX4032 (PLX4032) is… read more here.
Keywords: melanoma; inhibitor; melanoma resistance; plx4032 ... See more keywords